COMMUNIQUÉS West-GlobeNewswire

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates
08/01/2025
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors [...]
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
08/01/2025
FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08/01/2025
EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing [...]
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08/01/2025
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
08/01/2025
Châtillon, France, January 8 th , 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of [...]
DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3
08/01/2025
Châtillon, France, le 8 janvier (22 :15 CEST) 2025 DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3 Les données de l'étude EPITOPE OLE ( [...]
Calidi Biotherapeutics Announces Proposed Public Offering
08/01/2025
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
08/01/2025
Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, published in Nature [...]
InkSpace Imaging Receives FDA 510(k) Clearance for 1.5T 24-channel MR Coil for Siemens Healthineers
08/01/2025
PLEASANTON, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- InkSpace Imaging, a leader in MRI coil innovation, today announced that the United States (US) Food and Drug Administration (FDA) has cleared InkSpace Imaging’s next [...]
X-tosis to Present at Seed Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference
08/01/2025
Company to Present Breakthrough Research Approach for a New Generation of Neurodegenerative Therapeutics GAINESVILLE, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- X-tosis , Inc., a pre-clinical biotech company transforming [...]
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
08/01/2025
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") ( [...]
iTeos présentera ses travaux lors de la 43e conférence annuelle sur la santé de J.P. Morgan
08/01/2025
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 08 janv. 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]
Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering
08/01/2025
Jilin, China, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing [...]
Black Tie CBD: Redefining Excellence in Hemp and CBD with Award-Winning Innovation
08/01/2025
BROWNS SUMMIT, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- In the world of hemp and CBD, Black Tie CBD has set a new standard for quality, innovation, and customer satisfaction. Founded in 2018 , the brand quickly became a [...]
Tecan meets revised sales outlook for fiscal year 2024
08/01/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan meets revised sales outlook for fiscal year 2024 Männedorf, Switzerland, January 8, 2025 – In a trading statement, the Tecan [...]
Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference
08/01/2025
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective [...]
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08/01/2025
News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and [...]
HOOKIPA Pharma Inc - FORM 8 (OPD)
08/01/2025
NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name [...]
Rapafusyn Pharmaceuticals to Showcase Its Molecular Glue Drug Discovery Platform at WuXi Global Forum
08/01/2025
BALTIMORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a pioneer in non-degrading molecular glue therapeutics, announced today that it will host an executive roundtable at the WuXi Global Forum on [...]

Pages